0001477932-21-008000.txt : 20211110 0001477932-21-008000.hdr.sgml : 20211110 20211110161414 ACCESSION NUMBER: 0001477932-21-008000 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 211396751 BUSINESS ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY STREET 2: GALLERIA OAKS B, SUITE 125 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY STREET 2: GALLERIA OAKS B, SUITE 125 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 8-K 1 vnrx_8k.htm FORM 8-K vnrx_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 10, 2021

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36833

 

91-1949078

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification Number)


13215 Bee Cave Parkway

Suite 125, Galleria Oaks B

Austin, Texas 78738

(Address of principal executive offices and Zip Code)

 

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock,par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of  the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

VOLITIONRX LIMITED

Form 8-K

Current Report

 

Item 2.02. Results of Operations and Financial Condition.

 

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

On November 10, 2021, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2021. The Company also confirmed its conference call to be held on November 11, 2021 at 8:00 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

 

 

Description

99.1

 

Press Release of VolitionRx Limited, dated November 10, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VOLITIONRX LIMITED

 

 

Date: November 10, 2021

By:

/s/ Cameron Reynolds

 

 

Cameron Reynolds

 

 

 

Chief Executive Officer & President

 

 

 
3

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

 

Description

99.1

 

Press Release of VolitionRx Limited, dated November 10, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 
4

 

 EX-99.1 2 vnrx_ex991.htm PRESS RELEASE vnrx_ex991.htm

EXHIBIT 99.1

 

VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update

 

Conference call to discuss financial and operational results scheduled for

Thursday, November 11, at 8:00 a.m. U.S. Eastern Time

 

·

 Healthy balance sheet with approximately $22.9 million in cash and cash equivalents

·

 In advanced term sheet negotiations with three large multi-national veterinary companies on potential worldwide licensing/distribution arrangements

·

 Expanded the Company’s intellectual property portfolio

·

 Made significant progress with the Company’s Nu.Q® NETs development

·

 Continued focus on, and made strong progress towards additional new product launches and licensing in both the human and veterinary spaces worldwide

 

 

AUSTIN, Texas, November 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the third quarter ended September 30, 2021. Volition management will host a conference call tomorrow, November 11 at 8:00 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.

 

“We have enjoyed an exciting quarter navigating the due diligence process and negotiations with three multi-national companies to advance term sheets for Nu.Q® Vet licensing and distribution arrangements and anticipate signing a term sheet with one of those parties before the end of 2021,” commented Cameron Reynolds, President and Chief Executive Officer of Volition. “We have also made progress in other key areas including our Nu.Q® NETs and Nu.Q® Capture programs as we shift gears towards our goal of becoming a commercial company with products.”
 

An interview with Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, Cameron Reynolds, President and Chief Executive Officer of Volition, and Terig Hughes, Chief Financial Officer of Volition.

https://youtu.be/-ASwi40hfPY

 
Company Highlights

 
Volition Veterinary

 

·

In advanced term sheet negotiations with three top global veterinary companies and anticipate signing a term sheet with one of those parties before the end of 2021.

·

Published two abstracts at the Veterinary Cancer Society Annual Conference including:

 

o

 the first data published in relation to what will likely be the second Nu.Q® Vet product, a disease monitoring tool, on track for a planned launch in 2022; and

 

o

 the first study using Nu.Q® Capture as an enrichment tool in the plasma of dogs with lymphoma.

 

 
1

 

 

Financial

 

·

 Cash and cash equivalents as of September 30, 2021, totalled approximately $22.9 million compared with $19.4 million as of December 31, 2020.

·

 Cash burn rate averaged approximately $1.7 million per month, lower than the rate during the previous two quarters and also below the Company’s expectations.

·

 Net loss for the third quarter of 2021 was $7.2 million versus $5.6 million the prior quarter with this increase primarily due to non-cash items.

  

Personnel/Operational

 

·

 Dr. Gaetan Michel, Chief Operating Officer, has relocated to the U.S. and is tasked with expanding the team with roles expected to be filled in the quality, regulatory and manufacturing functions.

·

 On November 1, Mr. Nick Plummer joined the Company as Group General Counsel.

  

Intellectual Property
 

·

 27 patent families (plus three in-licensed families) covering both human and animal use of Volition’s Nucleosomics™ platform.

·

 82 granted patents (12 in the U.S., 14 in Europe and 56 rest of world).

·

 82 patents pending.

·

 Continued focus on filings during the third quarter of 2021 and expect portfolio to grow in the quarters and years ahead.

 
Publications

 

·

 Volition’s list of publications and abstracts continues to grow.

·

 Year to date data for Nu.Q® has been presented at four international conferences and Volition has collaborated on four clinical papers.

·

 These publications are another very important step forward for the Company.

 

Clinical – NETosis including COVID-19

 

·

 Volition believes the Nu.Q® NETs assay will have wide applicability for monitoring diseases with a NETs component (such as COVID-19, influenza, sepsis, autoimmune diseases and cancer) and potentially to risk stratify patients for treatment selection.

·

 Volition expects to register CE marks on its first NETs product, across multiple platforms including ELISA plate, automated beads and a proof of concept on very high throughput platform by the summer of 2022.

·

 Volition intends to register the Nu.Q® NETs product with a broad almost C-reactive protein (C.R.P.) style claim “for the detection and evaluation of infection, tissue injury, inflammatory disorders and diseases associated with NETosis”.

·

 Posters published this quarter (at the International Society on Thrombosis and Haemostasis Congress) showed that results on admission using the same Nu.Q® NETs assay could predict future COVID-19 disease severity and that serial results correlate with disease progression including 28-day mortality.

·

 The Company has further large studies completed in COVID-19 and sepsis which are now awaiting the finalization of data and publication, as well as studies in other diseases in progress with results expected in the coming quarters.

 

 
2

 

 

Clinical – Cancer

 

·

 The Company has completed preliminary analysis of the colorectal cancer studies (both asymptomatic and symptomatic populations) conducted with the National Taiwan University and has submitted these findings for presentation at a conference in early 2022.

·

 The Company has completed preliminary analysis of the lung cancer study also conducted with the National Taiwan University and looks forward to reviewing the data with Professor Chen and his team ahead of publication either through a clinical paper or conference abstract.

·

 Volition has also been in active and continuing negotiations in Asia this year in addition to platform development on its first human cancer launch in China.

·

 Collection for the U.S. EDRN study restarted in June and enrolment has been slow but steady. The EDRN have diverted some efforts to drive recruitment and the Company anticipates study completion in the fourth quarter of 2022.

·

 With regards to Volition’s U.S. blood cancer studies, the timing of expected completion for each has been impacted by the COVID-19 pandemic due to sample collection and protocol issues.

 

o  

Given the pandemic delays in the larger NHL study (of 1500 subjects) the Company has taken the opportunity to alter the study protocol and are in the process of upgrading the platform to a high-throughput platform which will help facilitate an FDA compliant product. Consequently, Volition now expects this study to initiate recruitment in the first quarter of 2022 with study completion anticipated in 2023.

  

Upcoming Milestones

 

Volition expects to achieve the following milestones during the remainder of 2021 and beyond, pandemic permitting:

 

·

 Drive revenue in the coming quarters in the following key areas:

 

o

Licensing of its technology, with a particular but not exclusive focus on Nu.Q® Vet, with the aim of signing the first term sheet this year,

 

o

Processing samples at Silver One using its Nu.Q® Discovery assays, and

 

o

Sales of its disease monitoring tests (e.g. COVID-19, sepsis).

·

 Continue to progress the research program for the use of Nu.Q® in NETosis, in monitoring disease progression of COVID-19, sepsis and potentially other diseases and as a possible companion diagnostic for a treatment for sepsis.

·

 Continue to advance its previously announced large-scale blood, lung and colorectal cancer trials in Europe, Asia and the U.S.

·

 Publish several abstracts and peer-reviewed scientific papers with clinical results showing the robustness and utility of its Nu.Q® platform.

·

 Advance the development of Nu.Q® Capture.

·

 Continue to file patents to expand and extend its intellectual property portfolio.

 

 
3

 

  

VolitionRx Limited Third Quarter 2021

Financial Results and Business Update

 

Date: Thursday, November 11, 2021

Time: 8:00 a.m. U.S. Eastern time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13725016

 

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with Terig Hughes, Chief Financial Officer of Volition, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations of Volition.

 

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until November 25, 2021. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13725016.

 

About Volition

 

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

 

Volition’s research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

 

For more information about Volition, visit Volition’s website volition.com or connect with us via:

 

Twitter: https://twitter.com/volitionrx

 

LinkedIn: https://www.linkedin.com/company/volitionrx

 

Facebook: https://www.facebook.com/VolitionRx/

 

YouTube: https://www.youtube.com/user/VolitionRx

 

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

 

 
4

 

 

Media / Investor Contacts

 

Louise Batchelor, Volition

 

mediarelations@volition.com

 

+44 (0)7557 774620

 

Scott Powell, Volition

 

investorrelations@volition.com

 

+1 (646) 650 1351

 

 

Jen Lewis, Mind&Matter

 

Jen.Lewis@ashfieldhealth.com

 

+44 (0)7809 867943

 

Joseph Green, Edison Advisors

 

jgreen@edisongroup.com

 

+1 (646) 653 7030

 

 

 

Safe Harbor Statement

 

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the success of negotiations and the timing, completion and execution of term sheets and/or agreements with third parties regarding the licensing and distribution of Volition’s products, the timing, completion and delivery of data from clinical studies, effectiveness of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, the timing of product launches and publications, and expectations regarding Volition’s ability to transition to a commercial products company, its future revenue and financial performance. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

 

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

 

 
5

 

 EX-101.SCH 3 vnrx-20211110.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vnrx-20211110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address Address Line 3 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 vnrx-20211110_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 vnrx-20211110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 vnrx-20211110_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 vnrx_8k_htm.xml IDEA: XBRL DOCUMENT 0000093314 2021-11-10 2021-11-10 iso4217:USD shares iso4217:USD shares 0000093314 false 8-K 2021-11-10 VolitionRx Limited DE 001-36833 91-1949078 13215 Bee Cave Parkway Suite 125 Galleria Oaks B Austin TX 78738 646 650-1351 false false false false Common Stock,par value $0.001 per share VNRX NYSEAMER false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 10, 2021
Cover [Abstract]  
Entity Registrant Name VolitionRx Limited
Entity Central Index Key 0000093314
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Nov. 10, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-36833
Entity Tax Identification Number 91-1949078
Entity Address Address Line 1 13215 Bee Cave Parkway
Entity Address Address Line 2 Suite 125
Entity Address Address Line 3 Galleria Oaks B
Entity Address City Or Town Austin
Entity Address State Or Province TX
Entity Address Postal Zip Code 78738
City Area Code 646
Local Phone Number 650-1351
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock,par value $0.001 per share
Trading Symbol VNRX
Security Exchange Name NYSEAMER
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://vnrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vnrx_8k.htm vnrx-20211110.xsd vnrx-20211110_cal.xml vnrx-20211110_def.xml vnrx-20211110_lab.xml vnrx-20211110_pre.xml vnrx_ex991.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vnrx_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "vnrx-20211110_cal.xml" ] }, "definitionLink": { "local": [ "vnrx-20211110_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "vnrx_8k.htm" ] }, "labelLink": { "local": [ "vnrx-20211110_lab.xml" ] }, "presentationLink": { "local": [ "vnrx-20211110_pre.xml" ] }, "schema": { "local": [ "vnrx-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vnrx", "nsuri": "http://vnrx.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "vnrx_8k.htm", "contextRef": "From2021-11-10to2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://vnrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "vnrx_8k.htm", "contextRef": "From2021-11-10to2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address Address Line 3" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001477932-21-008000-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-21-008000-xbrl.zip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

YS**DB1&-GJ'E@^R/Z +"%3/2:CG.5[/Z??Z1]&4+L369PA\%JRP M0('8,#^"$'&\)""-0YK0$#[@-2(A\^%3%Z;RR.K0QXBN]PPO5P)^#GX!U3V, MG;O;&;S?<$P0YS"ET499X+_"F 1=N(DB>%01'!X11^P)A=VTNPB3?X?JQUSF M!7*""1_N.+[NK(18#UUWN]UVMX,N94NWW^MY[M?/DVFP0K'O8*(F.D"=/$KU MHHOSKJZNW*0UEU:4NSF+\C$&;FY'RCD>\F2X"0V22;T@#(P*]9>3RQQUR/'Z MSL#K[GC8D;,!D,X'HQ%Z1 M(3 _%?BU)XCA>1\I2Q\:LK@I]94'NA5:?U_D#8IB&MR0?Y3LE M6N[V4O/?=?BI\)EXT917XQM.8$:%'[W(^FEDPZ;OT,MF^QC7]"S+U1Z];)9/ M(O\'TZ)J^-E3JYO32!V:R$\%@V@GY)Z#PMRBZJ!FQ4WZ3Q;VI.=#WS0H]!JI MM9NR:MY<]IKTR%'07=(G-T18]MSOJ0]JW^PY/2];GU_)0]]&5&[_-W,NF!^( MO+\DE>N.IMTMVE*Z&Y9[DQOPF?0RA1M0NRT5J]PGMC;E5=$TR83!9A*(D:@T5>E\&+#(Q)&J0<@M@Y%=T,]FO M)JMB!CY"\U*93:FRFQUE1> MXT)C"XJL\U.N\D$#2F1M@;^-$5MBLOR=T:U8C6B\]HEYF3>HFUSL:PT7EWRM MM 5XG'=G6/[S$$AC( NRN D<[C:HFW$URUU)U^RVH#59WA\*HA9 4N?+N&.D M8I!J4')KJ\J8!)2M*4MN(4Z%M#*B&WGJLA_1T'Q=<2:JR57FH@2*JTUM2 N MNMRE8?4IA$(2"UDPJ&AKM'W$$;K;Q'/$C&F?2IKDJ&JM",VQO36$5"P9<% Z M2(76*C_S=^-0+GQX@=-_5YS!P*AODHDSIHN &,2MH:7>GP$=&03%*-L@W82A MG!N>_9I@@CQCREIMDP#5F"W"HQ&V!ARS-P,TF?+P6X6 UR)B^L_(M6^;F/ZE MQ/1;3$S_!<3T6T3,X!FY#FP3,[B4F$&+B1F\@)B!;6)&\N,]F]$M.9?IJ=(" M+56C6E:.LK:14G%VAA.EAWL&*L(V)R)\,"X'(B,;QAF1W:+@F)X.N M&09J3>8@:$4MH*'.5QF)3 M%L04LIC3" 1:8+#_+\Q:&?5UF.E$S0)CMY314 M%2U P6BJS,%1"+G2 @0/#"D0D2Q%\AR+>GZ5W2\6VOVA3MP,%.?MYG"8E2V MY*RY,BPR $XC( V!),8^-F/.-X@]"QY-B!6$C-8-(%7T[9+!VV)%*[2U@PV"ILAME,I Z2(06*C]COGIY M;[J/YU272ZF]F9IK3>4%+S2VH-HZ/^529QI(11:_X+>[8"6-(9,2N6#352HPD#/S['"U@ M&[.[R#1^)@PZ[YQ_6A2 /3!NNY$4K">,683)5&9?Y16MI FI2 MSEO$6"HS*I1D%ZT-,ZT/[W_^Z?R7(/AR.;HA5RI=%DQ:TM>,6I:1%;=SXD[= M4F.9#H*=^I_M.%W2#CMA_.[Q^"4UT$K)L@V<3![/7$%_1,U(ZGHNFR9)D,1! M.VX_B<9J9E=4,T)U.N>6I7:IJ2 9,SR7! (G6T-=D,NEX9(90\9*+%T(YGD*0D6MAR(@9 MIA]8%FZ[$US^WW5/4_!% + TW;7A%ZVYM8MN%*U6JW#5"97.HW8<)]&7VYMQ M.F<%#;ATH%/6VK=RO52U2\[.SJ+R[%YZI%Q/M=B/T8GVX8#<\*XIA[M1:0G5 MHQFI5;A/P5X6N$-!T@XZ2;@V60MH$++EH95@(S8C[O7OT>!QS >IUV&JBLB= MB/H*UB+$6#:9:S:[:#E!.=_PB%VO;PY$=K. -6EXL1!@+GHVXD+#M$A;6KR! M P<-V-K"2F#9OALWND],EELGC+>/A 1/JS\@I9(,:F]JK*:I MW?V:0)])/4BG:"1KK&&@'K_K9] O]6$#Q5>8-L(8*N,(/#L00R9B^.C MH'DUT!<2+Z(=!**55M"RP77!= Y;G4]:K>R\KXH%E8TYH::!%^X_T#)#HTW$ M_#!DFJOL6F9N)]N<*%Y(O8"_1*%T2&@,HUE=+^+78]%76 MN-DXT=!K&OY$6_=>MM$FY2,7[&Y93)_VSU4S\%SEA?LO--S'AM#83NAZD($G M/N/;,NXTZ-HF7M3?H5$_815M"GI9!JC,[@5J3)8TX:^4>Z$_0T/?8/$'PMY^ M'?:V;ZU,V>/R!N'=>Q[WCRQVOPFSPB,V]#V_O]42MI ?UYV(_YAC%YPE_ MV,3+_=2]'FKUP+?_RI["?M3"CSU&F>KC%'L"ALI8*O[CBU.;^&J]'WR\HK7) M)0)Z]P7L:4;K81\J_/!BE*A53A" N@LL8CA7LK$(.E;Y@<4H.NL<(<#]5W-K MF>RKHEC*75U@J@G72/TP8Q2;C=X06(^5X"FW7.:W\#NA.175H*MT?I0QBLMZ M5PB(AYJYZ6;PZUO^'>^N3NK[V:PN:S3I_9!C%)6G7>*C'QBS9/JU$U#1RN^: M#T:-Z>L8(]6P= G9;Y.TIQ-WK;TFT1RI_&!C%)9UCA#@3C1U-\*,-\54U:3P M%Q(_K!BU8Z47Q 5[O4[G5.:L_N:&:J4?88P*LCSZ"C^&SC@[H?:GG%/ M[AZA]]\ 4$L#!!0 ( ,:!:E-B%OQ$Q0\ ,1I + =FYR>%\X:RYH M=&WM/?USXCBR_XH>^W:3U(O!!O(!(5QE")FE-H$4,+MS]\LK88N@C;&]DIS M_?77+=N R20 9+-)355B2VIU=WJ;TF>RC]&0Y<\,"&Y[YUGK*R9(9;]TKXS3SCVIEH* 7]/1DF8_.,P.E@G(N]_CXF!WUA)OUQ5TN;UJ%'/=< M[K'O7]K7F4EWM;C_M&M.">K)OB^&5 $6".G(,/-&_G@&B"&9G0($S]D[_^%% M.*=&P4K@V*$00-UX DACDT!*6F%@WC1,:SHP-?%C0>-OE4JEW @9DT ?2;ZH M8]XTK=SWF^N./6!#:G!/*NK9;#(*T+]?/@&V)EWG>LXPWRSDL+E'Y10RM/)G M^L]A JV.2O,F[GR4BQI37?G"KL=15YYT=1A?S&YHF.=T6;#^4I2/<] ZD0GI M%_/6R7/T13V2 :$TA.^RZ6+VJ>SIWDG+ G1L/_246"8P4>."8:$22Q$KY: U MZ2B%,M0X6(35I&D!?&A;.& 1*M*XHS182#4V+!CRX(FIDN-#UO:'V,^"'S,# MYH!1IUI17+FLBNW_?WJ?!4VHY*)7E?\QC$O?#H?,4Z0F&%7,(;TQ026]H5(Q M81C5RI I2G 2@_T5\H?S3,WW%(PPND!TAMC1TWE&L9'*17J6JU9RT=P]WQD3 MJ<8NBSH8U.5W7OG/4"K>'Y_U87#9,@-%%!\R23SV2(0_I!X@[_"'>.2>PV7@ MTG'9\SUVM@Z8LR$5=]PS7-97Y9.?DT?![P;Z>8]PYWP/Z;UL_+Y7K?!1&?%F M(OJ3.P[S])\PKUJ0L6J*I_S4V?2Q,/VLS0XC)9K:#Q*DMM(F%:HNU>&<7_?$_R8>"R MO?C= "W$'DJ=D4AD=B0=8'(N#2.:;G8._2C]4.@G;1[+,:FX7L\R->[.]-(D M3]S!YSYG@NAIV4(/56O\EEZ4IX.KR:LT] "8YCO)$]AJH2Y!E:I3M))QT[8) MFLZ2KDE+\IQ,DDNQ(X$3>CQBS;?.Y80'0T9E*%@UMJ]E:$N&)TW),XZ?@]49 M4%B&.7 Q*;IQ+7@P_^T3F*#CP-[9GEH&J?+%*ZF8&X\O+YGG#[FW".RJU*1 MY-+8IXC.I:4W-V-2P:G<:_ZF6B M81']XNKBIG']S_*<[28W%^VOC6:9 +PS,F/V;= _)A!]J83OW56_-1O=^B7I M="^Z]4XE%[_=S=R=>NU;N]%MU#ODHGE)ZM]KOUXTO]9)K75ST^AT&JWFCA'Z M@\H!9 7*]P[)9;:6)7GSJ%C:$1*[7/6*#*BW0$I/ Y6I7K7:-V2I'TVBGID0 M9@6'?6K\-N\J$8GJ!^0N2'6[WNR2=OVVU>Y^0 )OO[4[WRZ PFZ+@!)W05.) M52"M-K&.]IT#TKHBE9Z 6+;[:YW,:/E$PR]J7>QDE0K%#\0>C#J(WR=M%OA" MD?WDF5'P<4PJPAXP71"ZF3D'93+1QY>T[5;',/4HLGE=].K R"&,&SAT/ :4 M&&0*3?^!#7L0VUGF(<&!"Y1TT>K\N&-+N?*>+\#+&V /;#"_9?/L"?P99F,Z MDDI-:*C\='*BWT3QP#&$ \1FKAM0)ZKWF+/A03+_@.F!UA$B64&__K86^(6T MJ39X.@-.+9?'U%;:2:@,HD) M\81*(@-F8X+A$.X1KB2Q(1R%<0=/,%\:HFW1SJPEXC/QZRL$-GD?02F8/Y\] M,*&X3=T8/^4'*'S;%^OG);?AV;X ZZ>KEQT%%JD6%9AJOO,ZLX9%4TP.%0N$ M_X#SH5V[9"Y]!!/WO#G3XO&4>4<_IQCUXY9NX2SO=XFNN,N@#9S".N48RR@< MGQ8*G_Q>F]]=.FK$91);J\6ZS"_!KU*Q9)Z_R\'XQ:P\E6.K^BQ'_A>,( M)F7\ZYI[S%K=05B%O'5$OC!&:O2!D5LJ[A_I^*70G[Q5)6K#C,JOSJA."#D1 ML?)'3WESN+PE)8%.;M4D#V M8Q(P&0\$\)0'U"5LQ.Q0\0?,T<$F TSJ.00()$CAP99QVF7Q\_\LLK]TD5&^ M+P2CZRWK+!>D:Q^<[.W ]];.TXZ/3,,J'"VO\FU;=*:5JU]^.LU; M)V<2^KDL0&*(IZDY)"!2;HC%#P(9/ 7B'$8^D@ U?45H$+@0N4!(LJ/Z]_X5 MF#.(PJ,RFM#6#1YII,O ]#Z6SKP[!N$DQUS_$:G!1J29G!J_D3YW49ZX!.%2S'. 2N4#H.&GK^RY,CN/037!,[63Y M30OG^O&! GL\!0H/#LV-WCU&.=?L*PTR>;/@I-!I:;V#\$5R NFZJ$79QKR]2$$'B#J0;3G ^%Z54LGQ>+9O#5>.[=Z M)=TQ>4#/+'TD"(4,4<)!1]HA2%LQ?Q1+.XIY!SP]#.0 ]L)69-\Z(;6K-LD7 MS"QT?%IY7VG/X%7X1T+*/"H;6%(\KZE,D MZ(Q%J]]?(XQ]]_(*-!KV#)$OVE>KZ!CY_=[!:M(;]?V4W_<@OPTI0R8^I5A+ M<8$9Q7U[-2F.^ZZ\3__^CE(F<3'XIVE %*4'3$"",9PN $_> M-CO83&S^Y(RL-3DCNW3GM>D!DFM7&%/.K^1/>D$ MAV1YGIGV??-04%V-Z8R'/=_=EP=_1PX>O]G^?S,^N*0E<&(0P1@\#CB\:4\L MQM]FNWYY$A(9PK&5[VG%6[TRB3X56-)1OGU_&%!!'J@;,O*_9M8T+1+@[9/! MPO,\'W)K"-090DGV@YC\[=7*A MYZ/>(;F^KBWG] MS!C3AW:>5$K].14#+="_@=;X;@ M9P7TV7 2W99$-NNYW#%._LAA:EQ;) -:!'O@$L:!!E//QGHR,5^X= M*AP9;8,XRW*APCZ=Y$*S&I@,Q9=L:P6BW_KUK-)J7]68WLBN9U8+9Z1KO!?2.&3W!Z+U!^V!: MRX2ZCW0L]]:XD#"'^7:\[BXWCG]O73?PKE7[.[ENW."]S1W?CTSV4W<\;4U_ MM43%]ZJV=B5I4]EJ0[$AR6?-?!8PEJ&K]%&95L!$7#G#DS%7$\M9\\&28T-V M^Y3]R JE]+IXM+0:UDWMA'-O\K6:V9,=]=& ][@BI5+6.L18L#_Q4X$NF%VSBITY7C! /,:JEP\BC[N. >)K9 MSO%L!X>3T^Z/X$F)#'M_PGSH'W&@RVF/N]%4>G*JB(SP.0121$P4GZ4)AL(# MGQQACCY(,ODXA.8A>/#X9,/2[=PXAIXE1N/ZU$L?0O1@LT#?PF*C $^1X!D* MII"1L#XP=WPYRTXC(4-[$&.1W;UTOI56M#PR=]GRD,S?R$L)3AP<)S(#>B)# MZ$*)9C>PU644A(=Z'L1>ME8W,#;3H$S$Y@?5P(8\G +[>Z&$M M&AP'>")5: M[G'.OT)]YP*%3U^]@Z=XF6V4SD@@ M!\QUL-HUI=Z*X!&0Z=.R:1*:'6;)MVPG2^KZRSD>Z0++L^0JL0( 0[ H!)4I MRZ$)6R[Q. RO!0(# +E@-]\0M)V3@DN7,RWWVGY27]PQYRK=9>V=DPJEI>8W9N5GTFY7)\" M_1ML,+RA6TSUN_O8HN> M$OVAK(S^/!L;E4H6?J$M4T7/4,G1]U+AWC1YM]I[M6/?#RYM/H@X)([VAG,1 M1S;-E]4/CLQB9IG%):Q=^;I;ZBPO("G(+:3\$,N#^Z>VOD9P214E^AK;/M+@ M8%"",0 X=/3A#?U-3/V]/>+$'\G8S6&"M7S ^RS1/+%D/1>T>,:.D;D2SJ+L M//^!JSH[^OY5XVOSHONM7?^;?@-GU1#M=J;Z&Q6G_PJYB$/2]7/K0SV@G:YP M.R%DGS8-L2JM=V6BJPMQ$B(!(:;3$$Q4>@RRYS[F"@A(9\)Q!\P80@_&:' T M5 -?@ @YV4V'R#N,'K?B^L#98VW^/%/88(3S4GUS%X<=MT_M*\\YQE_+,#<2 M]>)7I,KSX<$SW\_85D[Q95PFKPJV8[PV\_F0"AM6%_?]PMXX3]3KO;'@\>N]7.9*O+Y.S7.ZS7S7*6RT18EHH),SKAZ2Y[OW_^]OBT M?7+T!E[9_'/YX/SX[3MZ\N+U7A9&QX':%\?_=^1&>>VL7=8 M-[O99;FXR=MZ2)XW@)(7!63E+>0(#__>=NMK86%O?W-C:KA;S42N92YV>W[ 3 MF4@\]_TTU44:P3R78VEB]J^"&QB+];O]'GLC4YY&DBMV+FRA$ MM>RG+ ;V-S^]OJ-.\;>6O8H>V1W\.>2+5=&=^. =?OSO M^_X+MR$_]X%.A\((@!2+N%(LURR6-BH #,,22@@=G0G#$W";^NN9$\S7=2;1*NW+.) M0+*<>41#AB>U502FYO"QK<0PW^%%KG<5('U[/#.0?X=HWKTTD7$^AL5T__R" M14*IC,0U5X *EB:& M_S*_#7+?&,".4\;C:X15#$1@$@^Q5(QT+HF!6 >^?&R$8 J6)%@"[$2VT\!? MK@5\"=S'3%FDDXRG$K8!4,UT#@!$CC311L6 4S" !/I"(;\"?"LWYN[%O 0D%.)*"\ :("NP,3S*<#1 MY$.0F?II0^8]!_RP\+<P1 M,/?OTZ-+RV)Q+93.$+F>-@1!.\AE6I" !YT :+!%+"TAR)+0K(":ZPDW,>A2 M(!H\(>-JX?>XB'*@=-#'QL+I6B75(J<<:'\:XP(V1K_7. !*1?BJI/@*XO!? M*$4? 'YUR?R8Q@IJS?Y/%Y?'IRUV*6ZXK>LVW9;3:%?.SD_%Q$ZD$2NE.L/: M;=:@&K\\_?GBB.V_/SH_/M@'?>7CZ?E_7K&72 /][F[X@/[L[;Z"8P5]"@[% MZ=-Q32TT->69LT%0GPM2GU$EI$/-2?_^Q>O?@EC5A9S2]NGH+:[,B[*'#YA7A6.1<*@NK >&/ MNRE@EP,@^TGG$>+)C$Z\[G1B?Z#_!KKBUP(@_TE/ ?9 8>(F E #\8532?FU M''%ZA$<6%_ ?"7R P $$'.&YXC'?)L;G!'@EM0'@7AVH:0.6D..SO/8CZ T5 MH\#I;Q7Q#@>!644R0^0CKH\?U7406J].!=-#6+:&T\]@^[C*@8 %"=J[0%MG M2#C9\C2 V\%9 '@' &6@+; ;IZE6,=#B&6 0<"5 5ES"P5B*(3NZ$1&L$8#^ M80BB!P ,(P;\[K"Y@^'*:L=12U8*3!%X(GQW)8#TC.#X*%(%ZMQ,%[? CI%P MPF4T_WS L[PP?AJ>P*MPAJC2RF'.1H*;BH?C'",-)PD+'PC8OP,F <(0\;LC MGCJ@>AYO.QYB>P,3\'M@'MAXWD])JS'7$EZCV0]-AUWJ! QX>,Q;O^40V,=* MP!Q*/DJ!Q\C(LL-*LK.3DX/60QRX$YF7,-V(O2M&P';"$BL_1!.>W&:6?B'\ M]HK7XSS/[,[*RE07>=$9B)7V_L5$KG7'P[.?]U:*UP\]\PQWVO06^\S#K::' MO6[CT]7&IVN-3S<:GS8NH=\X6W_.7S+ON@G_"VCN=4GV#G0_A?J?7=()UBEK M?ATBP0-N0'-WKOCSPR[J>W1J_,$:>Z050#7]VXO^BR7;%?1Z@EY02^FO [P,,U[$)'4N13 M=)NCIZ"F#)=ZQ\X] +W@]7N(356<9L%X_<.]B_K>IC6>PU :,&W 6N(L*T\, M=#\C%!$7:L^3,?=VD))7Z&@<.!*PH)7=JNFAYNQU,M ^4&T&%1*T=)W*7!M2 M\[56+?2I(69>!X\(IV80C_XOUR/-?-4VR,6RLLVSOR.=%_$YC MO/3W!Q BV*Z%'[+!V%1KN1<;^O'#^>'1>?O'#Y>7'][OL(%"E.]E-\R"GA3O M,@K^'I\>'F&X%\,W3=&;WF\E@1+>?\WX2+0'8+Y=M?D01MD!6V_"I_:OK^\C MM.:W_#C=7G,::&G:/.N=S\&TTIU\6T@,&1[PLT6W8 LX7\X5AICO"K>1BFG@ M)6*&/_2V.VOE;V[H0Q'YD7LT3C%E-Z(M![RYW$H2'BP@3_8&;$M=2%)>W2^Q"]=H^^+/*2-H97Q$TF MHMP9#D_\ $[1>:FMO<4/[JT7-@'T_&&STR]/ 0:S -D?UCL;Y3,'#NQ4@OY]I@H,)K!/6J:SV0LHLM\: M763LK4CA%-$?4:16J [[)IG8<3T)X\PG83CW[0(C^^PA^&66A_#,JKX50NAO M,G1[PM@T'KHT7V8*M2ARGB(D*=B),7;_PBO0;*\%L0M*DJ@2)'@*TEZQPHIZ MS*B6QQ(IH:U.9&3AX=I6?Q?]!CDH(\D3YS=;?38RG**U#MP YEX_\&9D]RW6 M6\._CPJD10+G^@9F N0(2THT>?7T@12 DPD28FQ ]2?.(7X&HJ7\,')V8$SFUB0ELB0&0J3H";$N M,XCGF"-F7&Y*+1$J!-(<>,O /(X0::4X4 V9(\B0\/L(,!G7!OP9],2G;AQ< M4A+>+!9B_"-UZ4_PS93)!+DNI_E%AJ>".4JE7\4;#4N/?#RP47 0SIEHLK>+ MR5O:RGJBU\&'C\>'[=[V,R=_YN3SG!R=K%)<"\ICO3,=T%H^]8FTF&U(11,\ MRY#@!A+]%$1)M="PCQ;[R")WPZ"'7:=HO+RT131&$SV@9PM0=J@*D?[*6\R* M#)"XQ?"49)(4J:C&4&6-YSD[Q)"%LQ$AB+C,[.&*PABO28B6"B"+-=$Y5U#\RZ'VF MQ-Q,B=+ZJS.8HY/CBWWZ1;@32T@4#4!O#5G=,!ZH"?#_(,DBD>7,N:BG; QP M1LM5%Z-Q5N3E^&PP=?D)SKOC=.C^]W):*/W3>/:T/D.@H3["4]O :(YQE 2S MW@_:@/@1)9;":[D 8^/E0>>\<]9YY=:#T7&9A(SB(!)CD3LB<:;+-5>%RR>! MTP!:=;^U6"ZM+=#Q\*DP4T?%/$FJ'ETWZ? M^"F?:4LF7I6K0Q&88"Z^]-E5QS,:8,BL NA? K7 E#((U#?<8&'S/%O,$\I M\QN.=:PG-#*,%@HL\"#C!$X+S]"EDA")\>0WL/Y(%RI&1366@&7#@A), N\N M4X.L0#]3[AS5-+F%OVM%'I$VE)8DW,&'[T+*ND/^P%CZ6VTL&DE0;T,1\\01 MX[+FNT;%?E@84E]=<2-F *&S#T6H$KF+$Y0'@/!V0I--QA(E*QQ/JB>,3[@L M*S*PZ$;)7TLJ)ON$9&BE.K=OC?,&E925"2L$SGZN#""9_2\%G_ MP;/QG%JTM-2B_G-JT9=83BZ'=5E6TG-(YNE:4_.,NV+1("^53%R.- ?>.T4& M32GIR!B5-IC'HKPY4W+;EQ2EX;"JC)1I&3G^7OL[TUGALGLINI.B[A>T*=(4 M@^)PR>6$I^RG5&)*2!#-N$I;#!*9YRYH:DDXQ.3)1OW/>Z2Q*X[96^3]K?+O(K$><*G_^ M8 QH]L1!?Z"5]\F4/EE7>'UX?NII"&.KJ$62;OD/= J189H:K0B4I3_=8N;@ MH"!7+X^G'8943 .1\RI&$L-AK ;31PQA/N<:B0V>,3!E4TCG*')V3"VGI*P[ MLGY1GB'X=BVD96M4W.?B?T^=3_[;V0 CJOL%4"[$BN@P!\#/XCEQUW(Q4TEF M @"K-"!JD$6,$!R(H3QB">=!;WE'46D)41N3!$2DSU\$\Q8=5U&%7F3P&)WK M"*LAT'G1;)7<2_WZ+5K4,E6F;[PT2L^G3Y4K>(#!WP)5^_37$CF$ C,G4"Q9 MV(:=OCOQ1/T2\+"WWNVBDO0)':>O9K@ 8F'.K_R@.L/(4I&BS,9&!2JXZ]Q8 M):J1*]2(L@#'-T2 J8IL9'B9)5B*"1R,/*3M)@^IL_.=2UZHC T!,X'F*$\[ M96\.]QT!2=^R!A4/ZD]AQ2\%L#8U;55Q1/04E"YB%%]NZ; T E0P,URQ<#H M2&;-\3FGCBSPQHIQQKXB;'6NYO)1I^+-5G,WUHZO-5:)K_<:G_8;GS:.N]Y8 MD[Z^WOBT>0V-E>KKC=7RZ]M-3S<:J]HW&O>VT;B+C<;U;C2N=Z-Q#9N-:]@, M(\Q:]S]EWN_T7BK0&G0JEI;)4I\YX-P29IG=M3_1IO@.B$D,Z7E51($JA'!( M2CC4,Y6,2#B8?7-92@,Q!4.E57%+L ?05 SEN]]XS!@%D M9"%N\=M6RFW J+*IS,X7*T_?QJE^XRK6Y^N3V;TQYZ3LJX0Q0>0_(AJG6ND1 M:!<^%$F-%Z("="PRR5*=8^^[UKS^Y_EF=-'$;+.9J)&#Q=2P=OL QC;+F2(I]Q\6(?24I[YU(4,;>NY MXO_^IW#!$?">FIHZ+H 4M^REZ(PZM=09%_I[]>5F[',4X0_/+2=/8=D-DY0T MP (3C4/'M=(_YLLVFJD1Y+5/J\" UC M#,C'0BUZ8+BX;(;F>X)4J5?XMYO@B7O$ZN<9FAR9U5OATD>B+:%,81S MDK5<#,'YF^<#13GF5-BJ^*3E',_!68FNMJ<-6]^9R.6;8&OYJC<1(JT %N<" M)>CDC3 #$)OW^F1HIU"4X8ZR#?U8EW$5HP? Q-+0K[+(78JC9\O-!/>=%$;M MASZ#W'Z!RN*U*5][4?>]I>5Q-65FX3]KZW5?XR&L>8>5J[[E MOA('[J4M EMAUQ9Q2\/LG*Y&6=HB:*Z_@+U*"5P\YMB(5[7AFVIEO?;6YF9[ MK;O9WM[L;;"7N5:*#8T0KY:ZL']V&M;295L ILWU#;:ZUM_^2FNYA$E69A** M9Z#3[_;::]NK[8W-S>TEKJ+6#O+XL+Z UK>WL0Q'.4BIYI[ C:&+7K65F1IG,=8 8V/P;6.NRXRG5J42]>);(Q=N U BRC:;GH MU:5].JOA_L<+L?E"+%CIBPM\!U7X@FL?6VMO=[KM_O;_9YCIVUB MI_56#0[UG7C ?P*[@R]6>YOMC8U-_]6KV9I;->VP,T5^DL*62\C*Z5G@6@]T MC\-RF45H>C_015X>]W+[BB^+W;U35UL;6ZMK/8RA5Q53Z(B:NSY"9'CUA""V M$>X90!Y)=2E4NXAU#/G=;4[*!$E\T19 #8"&QM])X>U?9B7ZRUL,T(62)@!C M6C ED*H84IW4M??J>/:XY"2YRA#I;Q!BQK$81*CHD07 MDA*440,KIXQ37W_9HM@/,2=,*DG@73>6-*'15=BPHWD'*"3Q ;>NL)U2:M"9 M$WFWY\*IM7Q2C+0^PP:S-MW;) 'D$-5R)BU,<<&$Z9]-BWA5'"L2AORIVOWT=##T%N/PEYN5R[E,ZZ) MN#FHEX"CG-0*!V=&\8U\;A_F$5XWLR!V2D1W!IY2G(I2I%A9&X4M(*?G2L2XG6!AA M=ECMEI/Z3Y^UL5E,1 +VZ ;= :"=@&,Q=2VXK+6'MM&+IWY MD?O6"GBI&;^#&0#'Q4!CBWG" C;K$;3%PMDZ2\Y#R)>O8J9I:8M0JK<151$2 MM=X$L1J'V[JI2&I,A3H.>RH"!4V> '=:DE"(7OU]N_]F2]_0]JM[T'N<#92N4DP9 6 MQE0?2[^@+\X,\=AT^>%LA_VI2_]71R;_\_GQVW>7=[T0L/'V-TZ.WC2.X':P MVEW(31GH/-?)PP0X_6&=Z +43_8CS[&?L3:M9=G]#XJ+Q>L$T;#T4?V]KD2R MQRD, \3_=VV-O>R^VEQ?WV2;FVL;_>[2(+T0D_Y"U/Z:B#GKK/TVD#(X3YOQ M\I&C98^]W%C;>,4VUN'(5]=OC< ^'%8^_*B_6V6X/Y->/@7\0Z3L1$PP,^^] M3&.*7K[GJ%H^;BJ =7=HW7_G=CR40L5CP54^_@9HP+/FK>XVV]K8W%Y;_698 M\Y=K'5\!H;45V9B]-4* 372$7;]2MA]?8_>O9:J/#X#3GT:XZ+\+6O,(KPOX M!K"YXNBK;+.[^A7TC"5Q],=H$979"]THJ6DM?"C8.V[ 2&$76&2+IOPC1NUR MC;9T0&2440XJC'-*NQOIJYY_V&&DC?U&*+!4?AYN+T>/K0^/)(*GON;GPM?4 M]S?W0X07'A7&.>OW(W*Y]+975\F'SF'$6,0^:!\^[1TU?'IT$XTI#%:-L38[ M!H5 M+&^*]X]KS2;F?_(=(N:['^8:D#G!:*D++N8ZDY%OA0'( M$1H#S/27">G]KE5&:[:Z'E.+*>W%%7-4%7'TW0K&E5'2N46$>[],7%Z+[%IW MR#)\&^KZ?!PK-W)0#K[@(0U1K=9=ZXL%IK*8:=EXD"BJ3,,ONX&4(?/4 V%A M.@K/MEU[P&T656XLCAA[&M9@^H8$[B6&!# "VDPB#24[ C!T% MXW"UEKBN2PF%T,O6J=CSUA5MX(#S)32U3HO"7!.\+=VTV[@I;6Z[@]?-36L* M@\^W50D-8EU7(5^_4V^9WJK=4.$QKD**NR"6&V Z99,C7@-4%>[TH::6ZW7D MNH>&@F.<=E@FD&7"4- 18-9IF':64R>4%G0'J_8A^I(WWTVP%EOL.FF7'U6% :T*50%T"H\X\*NM)""L[#,.N,H7EP%PP M12T7;LBELO/(.8N/]T*9BEYE'A2!(B5?+)4K("/QQ4H@4'"9.MR;!^O\0$A\ MFW#U<8_%H\--X+'##'J KP-W0^K"3(;:%6<1J">&NTB(<1=-7G._^\"'?,(, MQ<\#-H4] 0,OI_*]@=R+L)7(%6-%U(+:]V!Q^ FK65AP/0,ADYG \D5:4UK5 MPOT.H%?'FJ +(TRS>R?$+&I&&*D2OQ0H/VXI'L'NSL1WJM%>7[' DPFPC/0"K4M!-GB+4D8!C/9%Q5E).4<$KA+HOU)(4)7->U&'-W M<'\A9@YC*\ MV%PG@)&[-<[KD-9+V$1@_"C?9GPNLR\%\CS>8$];KMO])H_K" M!MB[>\/67_G73"M=CS$^".B5T(K"L3U'5>E>4X1QFE(9/@":=PV<@ZI1XUXS MR5+PO<$-U/DYR-:@LH4F6)\4*G0/]5GS?7:185^);W.)A&,+&Q<@ZZ ;('\II'%! M:<4GM5Y*L4:C#+998&,5;!.%N6(:!.V(!R%94-6)$X:WKXW:/0Z1R@.04&+F MQ!@C:0"3G+"PCS"'J"FG$D\-:P1=>6"=TH7-?)HD$+IVIP)J12S@R4= M*1+AUH)*0-8*CKBOKJNG:G;8/M"@5[3+45MSX]%R\%?*-+4N)&_*E)%VBVN:8)Q.GR?6!)@FIK)!X#IO97R M0S!1Z-? ?!4H:U3F6?^4$CC(#4"PV@=E 5AH9ZYPH-]<\=!O+FWHA]*& MY_2$!TM/6%^N.VQOH./IZ_\'4$L! A0#% @ QH%J4R=C!^MK! !18 M !$ ( ! '9N'-D4$L! A0#% M @ QH%J4Q+[CPO1 0 @P, !4 ( !F@0 '9N"TR,#(Q M,3$Q,%]L86(N>&UL4$L! A0#% @ QH%J4X:M4Y. . " 84D F !V;G)X7V5X.3DQ+FAT;5!+!08 !P ' , ! !V00 ! end